Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Crizotinib
Drug ID BADD_D00535
Description Crizotinib an inhibitor of receptor tyrosine kinase for the treatment of non-small cell lung cancer (NSCLC). Verification of the presence of ALK fusion gene is done by Abbott Molecular's Vysis ALK Break Apart FISH Probe Kit. This verification is used to select for patients suitable for treatment. FDA approved in August 26, 2011.
Indications and Usage Crizotinib is used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic-lymphoma kinase (ALK)-positive as detected by a FDA-approved test.
Marketing Status Prescription
ATC Code L01ED01
DrugBank ID DB08865
KEGG ID D09731
MeSH ID D000077547
PubChem ID 11626560
TTD Drug ID D03ZBT
NDC Product Code 0069-8141; 53869-2231; 68724-1020; 0069-8140; 72969-115; 53869-2230
Synonyms Crizotinib | PF-02341066 | PF-2341066 | PF 2341066 | PF2341066 | PF 02341066 | PF02341066 | Xalkori
Chemical Information
Molecular Formula C21H22Cl2FN5O
CAS Registry Number 877399-52-5
SMILES CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Intestinal perforation07.04.06.0020.000417%Not Available
Jaundice01.06.04.004; 23.03.03.030; 09.01.01.004--Not Available
Joint dislocation15.01.07.002; 12.04.02.0070.000533%Not Available
Joint swelling15.01.02.0040.005595%Not Available
Large intestine perforation12.02.03.005; 07.04.06.0050.000208%
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.008--
Leukocytosis01.02.01.002--
Leukoencephalopathy17.13.02.0030.000533%
Leukopenia01.02.02.0010.003463%Not Available
Libido decreased21.03.02.005; 19.08.03.001--
Lip oedema07.05.04.004; 23.04.01.006; 10.01.05.0040.000533%Not Available
Lip swelling23.04.01.007; 10.01.05.005; 07.05.04.005--Not Available
Liver abscess11.01.18.001; 09.01.11.0010.000799%Not Available
Liver disorder09.01.08.0010.005062%Not Available
Liver function test abnormal13.03.01.0130.007992%Not Available
Local swelling08.01.03.0130.004263%Not Available
Loss of consciousness17.02.04.004--Not Available
Lower respiratory tract infection22.07.01.002; 11.01.09.0020.001865%Not Available
Lung disorder22.02.07.0010.003197%Not Available
Lung infiltration22.01.02.0040.001332%Not Available
Lymphadenopathy01.09.01.002--Not Available
Lymphoedema24.09.01.001; 01.09.01.0060.000533%
Lymphoma01.12.01.001; 16.20.01.0010.000208%Not Available
Lymphopenia01.02.02.0020.001865%Not Available
Malaise08.01.01.003--
Melaena24.07.02.013; 07.12.02.004--Not Available
Memory impairment17.03.02.003; 19.20.01.003--
Meningitis17.06.03.001; 11.01.03.0010.001332%
Metastases to lung16.22.02.002; 22.08.01.0050.000208%Not Available
Mood altered19.04.02.007--Not Available
The 9th Page    First    Pre   9 10 11 12 13    Next   Last    Total 20 Pages